托里帕利马布加化疗与化疗作为扩散阶段小细胞肺癌的第一线治疗:成本效益分析
Longfeng Zhang1, Hongcai Chen2, Huide Zhu3
1Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
Frontiers in immunology
|July 16, 2025
概括
托里帕利马布加化疗为中国的扩散阶段小细胞肺癌 (ES-SCLC) 提供了一种经济高效的第一线治疗方法. 与单独化疗相比,这种组合疗法显著改善了质量调整后生命年 (QALYs),保持在支付意愿值内.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 扩散性小细胞肺癌 (ES-SCLC) 是一个重大的治疗挑战.
- 对ES-SCLC的第一线治疗选择正在不断发展,以改善患者的治疗结果.
研究的目的:
- 评估托利帕利马布加化疗与单独化疗在中国一线ES-SCLC治疗的成本效益.
- 评估将托利帕利马布添加到标准化疗中的经济价值.
主要方法:
- 使用分区生存模型来估计成本和临床结果.
- 经质量调整的寿命年 (QALY) 和增量成本效益比 (ICER) 是主要的结果指标.
- 进行了敏感性分析 (单向和概率分析),以评估模型的稳定性.
主要成果:
- 与单独化疗 (20280.31美元) 相比,托里帕利马布加化疗的总成本较高 (50,918.81美元).
- 组合疗法产生了显著更高的QALY,为1.59,而0.55.
- 每个QALY的ICER为29,460.09美元,低于40343.68美元的支付意愿 (WTP) 门.
结论:
- 托里帕利马布加化疗是中国背景下ES-SCLC的成本效益高的第一线治疗策略.
- 改进的QALY证明了在WTP设定的门内增加的成本是合理的.
- 敏感性分析证实了这些发现的稳定性.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


